SG11201810951RA - Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy - Google Patents

Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy

Info

Publication number
SG11201810951RA
SG11201810951RA SG11201810951RA SG11201810951RA SG11201810951RA SG 11201810951R A SG11201810951R A SG 11201810951RA SG 11201810951R A SG11201810951R A SG 11201810951RA SG 11201810951R A SG11201810951R A SG 11201810951RA SG 11201810951R A SG11201810951R A SG 11201810951RA
Authority
SG
Singapore
Prior art keywords
international
california
pct
receptor
retinoid
Prior art date
Application number
SG11201810951RA
Inventor
Roshantha A Chandraratna
Martin E Sanders
Original Assignee
Io Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Therapeutics Inc filed Critical Io Therapeutics Inc
Publication of SG11201810951RA publication Critical patent/SG11201810951RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111110111101110101011111010111110010111MHIE111111111111111111110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/214575 Al 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A61K 39/395 (2006.01) C07K 16/30 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, C07K 16/28 (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2017/036870 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (22) International Filing Date: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 09 June 2017 (09.06.2017) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/348,646 10 June 2016 (10.06.2016) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 62/406,779 11 October 2016 (11.10.2016) US MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (71) Applicant: 10 THERAPEUTICS, INC. [US/US]; 1805 KM, ML, MR, NE, SN, TD, TG). East Garry Avenue, Suite 110, Santa Ana.,California 92705 (US). Published: (72) Inventors: CHANDRARATNA, Roshantha A.; 26242 — with international search report (Art. 21(3)) _ Via Corrizo, San Juan Capistrano, California 92675 (US). SANDERS, Martin E.; c/o I0 Therapeutics, Inc., 1920 4th — Avenue, #2704, Seattle, Washington 98101 (US). = Agent: CULLMAN, Louis C. et al.; K&L Gates LLP, 1 = (74) Park Plaza, Twelfth Floor, Irvine, California 92614 (US). = Designated States (unless otherwise indicated, for every (81) kind of national protection available): AE, AG, AL, AM, _ AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = = = _ Title: RECEPTOR SELECTIVE RETINOID AND REXINOID COMPOUNDS AND IMMUNE MODULATORS FOR CAN- (54) - CER IMMUNOTHERAPY = = (57) : Disclosed herein are methods for treating cancer comprising ad- = FIG. 'IA ministering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent. = _ 100 = RARu = — RARri = . — RARy = — 75 = _ 1-1 11 in IN 11 in 25 71' 1-1 IN ei . ....... , ....... 1-1 © ei tIm's 0 I 10 Concentration (nM)
SG11201810951RA 2016-06-10 2017-06-09 Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy SG11201810951RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348646P 2016-06-10 2016-06-10
US201662406779P 2016-10-11 2016-10-11
PCT/US2017/036870 WO2017214575A1 (en) 2016-06-10 2017-06-09 Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy

Publications (1)

Publication Number Publication Date
SG11201810951RA true SG11201810951RA (en) 2019-01-30

Family

ID=60572126

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810951RA SG11201810951RA (en) 2016-06-10 2017-06-09 Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy

Country Status (12)

Country Link
US (10) US9907768B2 (en)
EP (1) EP3468600A4 (en)
JP (1) JP2019517557A (en)
KR (1) KR20190017950A (en)
CN (2) CN109310763B (en)
AU (2) AU2017278220C1 (en)
CA (1) CA3026563C (en)
IL (1) IL263629B2 (en)
MX (1) MX2018015352A (en)
SG (1) SG11201810951RA (en)
WO (1) WO2017214575A1 (en)
ZA (1) ZA201807809B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03819B (en) 2015-03-23 2021-04-20 Jounce Therapeutics Inc Antibodies to icos
EP4098257A1 (en) 2015-11-25 2022-12-07 IO Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
EP3468600A4 (en) 2016-06-10 2019-11-13 IO Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
US10213401B2 (en) 2017-07-13 2019-02-26 Io Therapeutics, Inc. Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
CA3073953A1 (en) 2017-08-31 2019-03-07 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
EP3709990A4 (en) * 2017-11-17 2021-12-01 The Regents of the University of California Manipulation of the retinoic acid signaling pathway
US20210008047A1 (en) * 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
GB201805963D0 (en) * 2018-04-11 2018-05-23 Avacta Life Sciences Ltd PD-L1 Binding Affirmers and Uses Related Thereto
IL311536A (en) * 2018-06-04 2024-05-01 Tufts College Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
CN109136373A (en) * 2018-08-27 2019-01-04 中山大学 It is a kind of for early diagnosing the lncRNA detection kit and its application of lung cancer metastasis
CA3124039A1 (en) * 2018-12-19 2020-06-25 King's College London Immunotherapeutic methods and compositions
US20220089540A1 (en) * 2019-01-17 2022-03-24 Board Of Trustees Of Michigan State University Compositions and methods for immune modulation and treatment of cancer
US20200352958A1 (en) * 2019-05-10 2020-11-12 The Trustees Of The University Of Pennsylvania Methods And Compositions For Targeting Retinoic Acid For Solid Tumor Immunotherapy
CN114761431A (en) * 2019-10-16 2022-07-15 株式会社Lg化学 Neonatal Fc receptor binding AFFIMER
WO2023097259A1 (en) * 2021-11-23 2023-06-01 Io Therapeutics, Inc. METHODS OF USING RARγ AGONISTS FOR CANCER TREATMENT
WO2024006732A1 (en) 2022-06-27 2024-01-04 Io Therapeutics, Inc. Synthesis of tetrahydronaphthalenols and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
US5234926A (en) 1987-03-20 1993-08-10 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5324840A (en) 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
US5612356A (en) 1992-12-28 1997-03-18 Eisai Co., Ltd. Heterocycle-containing carbonic acid derivatives
CA2138000A1 (en) 1994-01-03 1995-07-04 John E. Starrett, Jr. Retinoid-like compounds
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
FR2739557B1 (en) * 1995-10-09 1997-11-14 Cird Galderma USE OF A RAR-GAMMA SPECIFIC AGONIST LIGAND
US20030092758A1 (en) * 1995-10-09 2003-05-15 Laszlo Fesus Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5723666A (en) 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
DE69720745T2 (en) * 1996-08-28 2004-02-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) THERAPEUTIC COMBINATIONS OF RAR ANTAGONISTS AND RXR AGONISTS
US5739338A (en) 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6326397B1 (en) * 1998-11-10 2001-12-04 Hoffman-La Roche Inc. Retinoid antagonists and use thereof
JP2003502337A (en) 1999-06-11 2003-01-21 アラーガン・セイルズ・インコーポレイテッド Organosilyl compounds having nuclear hormone receptor modulating activity
WO2001007028A2 (en) 1999-07-23 2001-02-01 Allergan Sales, Inc. The use of retinoid receptor antagonists in the treatment of prostate carcinoma
PL208665B1 (en) 2000-10-02 2011-05-31 Hoffmann La Roche Retinoids for the treatment of emphysema
BRPI0410454A (en) * 2003-05-19 2006-06-13 Irm Llc immunosuppressive compositions and compounds
PT1937244T (en) * 2005-09-30 2018-11-07 Io Therapeutics Llc Treatment of cancer with specific rxr agonists
CA2651487A1 (en) 2006-05-16 2007-11-29 Vitae Pharmaceuticals, Inc. Methods for treating chemotherapy and radiation therapy side effects
WO2008137488A1 (en) * 2007-05-01 2008-11-13 Purdue Research Foundation Methods for controlling inflammatory and immunological diseases
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
WO2012112623A2 (en) * 2011-02-14 2012-08-23 Sloan-Kettering Institute For Cancer Research Rxrg modulators for the treatment of cancer
US10485780B2 (en) 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
JP6361039B2 (en) * 2013-04-03 2018-07-25 アイビーシー ファーマスーティカルズ，インコーポレイテッド Combination therapy to induce immune response to disease
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
US20150164907A1 (en) * 2013-11-17 2015-06-18 Angion Biomedica Corp. Compositions and methods for treating disease
CN105829310B (en) * 2013-12-20 2019-04-12 阿斯特克斯治疗有限公司 Bicyclic heterocycles and its therapeutical uses
EP3090066A4 (en) * 2014-01-02 2017-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
WO2015131176A1 (en) * 2014-02-28 2015-09-03 Podack Eckhard R Compositions, methods, and kits for treatment of cancer
ES2931337T3 (en) * 2014-07-31 2022-12-28 Univ Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
CN106604745A (en) * 2014-09-08 2017-04-26 细胞基因公司 Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-PD1 or anti-PDL1 monoclonal antibody
EP3267969A1 (en) * 2015-03-09 2018-01-17 King's College London Combination therapy with rar alpha agonists for enhancing th1 response
WO2017201200A1 (en) * 2016-05-19 2017-11-23 Orphagen Pharmaceuticals, Inc. Therapeutic compositions containing rar-alpha antagonists
EP3468600A4 (en) 2016-06-10 2019-11-13 IO Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
US10213401B2 (en) * 2017-07-13 2019-02-26 Io Therapeutics, Inc. Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

Also Published As

Publication number Publication date
US20220184012A1 (en) 2022-06-16
CN109310763B (en) 2022-10-21
US20180133180A1 (en) 2018-05-17
US20170354623A1 (en) 2017-12-14
US20180133182A1 (en) 2018-05-17
US20180133183A1 (en) 2018-05-17
US10004709B2 (en) 2018-06-26
EP3468600A1 (en) 2019-04-17
US10123982B2 (en) 2018-11-13
CN109310763A (en) 2019-02-05
US10004708B2 (en) 2018-06-26
US9907768B2 (en) 2018-03-06
US11648223B2 (en) 2023-05-16
US20210275478A1 (en) 2021-09-09
AU2017278220B2 (en) 2022-07-21
AU2022256117A1 (en) 2022-11-17
US20190105292A1 (en) 2019-04-11
WO2017214575A1 (en) 2017-12-14
US20180133179A1 (en) 2018-05-17
AU2017278220A1 (en) 2018-12-06
IL263629B2 (en) 2023-02-01
KR20190017950A (en) 2019-02-20
MX2018015352A (en) 2019-03-28
CN115671292A (en) 2023-02-03
CA3026563C (en) 2023-11-28
IL263629A (en) 2019-01-31
ZA201807809B (en) 2019-08-28
US20180338941A1 (en) 2018-11-29
CA3026563A1 (en) 2017-12-14
US20180133181A1 (en) 2018-05-17
EP3468600A4 (en) 2019-11-13
JP2019517557A (en) 2019-06-24
AU2017278220C1 (en) 2022-10-13
IL263629B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
SG11201810951RA (en) Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
SG11202000263QA (en) Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
SG11201908391XA (en) Methods for modulating an immune response
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201901126UA (en) Combination therapy for cancer
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201811549UA (en) Boronic acid derivatives and therapeutic uses thereof
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201808990QA (en) Compositions for topical application of compounds
SG11201808125RA (en) Methods for solid tumor treatment
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11201811225RA (en) Ar+ breast cancer treatment methods
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201807250PA (en) Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201900123TA (en) Compositions and methods for treating frontotemporal dementia
SG11201805204WA (en) Nicotine particle capsule
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists